Table 1. Patient Characteristics (All Patients).
| Characteristic | Patients (N=42) |
|---|---|
| Sex (male/female), n (%) | 25/17 (59.5/40.5) |
| Age, y, median (range) | 64.5 (18–79) |
| WHO Performance Status, n (%) | |
| 0 | 11 (26.2) |
| 1 | 31 (73.8) |
| Tumour type, n (%) | |
| Adenocarcinoma | 28 (66.7) |
| Colorectal | 20 (47.6) |
| Cholangiocarcinomaa | 3 (7.1) |
| Other adenocarcinomab | 5 (11.9) |
| Mesotheliomac | 5 (11.9) |
| Squamous cell carcinomad | 3 (7.1) |
| Melanomae | 2 (4.8) |
| Otherf | 4 (9.5) |
| Prior therapies, n (%) | |
| Chemotherapy/other therapies | 42 (100) |
| Surgery | 35 (83.3) |
| Radiotherapy | 17 (40.5) |
a
extra-hepatic bile duct (n=2), intra-hepatic bile duct
b
adenocarcinoma of the lung, stomach, cervix, urachus, unknown primary
c
oleura (n=4), paratesticular tissue
d
lung, oesophagus, nasopharynx (EBV+)
e
skin, eye
f
osteosarcoma (humerus), Ewing sarcoma (femur), poorly differentiated carcinoma (cervix), succinate dehydrogenase-deficient renal cell carcinoma (kidney).
Abbreviations: EBV, Epstein Barr virus; n, number; WHO, World Health Organization; y, year.